These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 33734715)

  • 1. Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System.
    Mendonça MCP; Kont A; Aburto MR; Cryan JF; O'Driscoll CM
    Mol Pharm; 2021 Apr; 18(4):1491-1506. PubMed ID: 33734715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of siRNA into the blood-brain barrier: recent advances and future perspective.
    Kuwahara H; Yokota T
    Ther Deliv; 2012 Apr; 3(4):417-20. PubMed ID: 22834073
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.
    Holm A; Hansen SN; Klitgaard H; Kauppinen S
    RNA Biol; 2022; 19(1):594-608. PubMed ID: 35482908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-assembled and nanostructured siRNA delivery systems.
    Jeong JH; Park TG; Kim SH
    Pharm Res; 2011 Sep; 28(9):2072-85. PubMed ID: 21424157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovative nanotechnologies for the delivery of oligonucleotides and siRNA.
    Toub N; Malvy C; Fattal E; Couvreur P
    Biomed Pharmacother; 2006 Nov; 60(9):607-20. PubMed ID: 16952435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the lung using siRNA and antisense based oligonucleotides.
    Moschos SA; Spinks K; Williams AE; Lindsay MA
    Curr Pharm Des; 2008; 14(34):3620-7. PubMed ID: 19075738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral delivery of siRNA and antisense oligonucleotides.
    Akhtar S
    J Drug Target; 2009 Aug; 17(7):491-5. PubMed ID: 19530907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers.
    Fattal E; Bochot A
    Int J Pharm; 2008 Dec; 364(2):237-48. PubMed ID: 18619528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological barriers to therapy with antisense and siRNA oligonucleotides.
    Juliano R; Bauman J; Kang H; Ming X
    Mol Pharm; 2009; 6(3):686-95. PubMed ID: 19397332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CNS Delivery of Nucleic Acid Therapeutics: Beyond the Blood-Brain Barrier and Towards Specific Cellular Targeting.
    D'Souza A; Nozohouri S; Bleier BS; Amiji MM
    Pharm Res; 2023 Jan; 40(1):77-105. PubMed ID: 36380168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug.
    Garbuzenko OB; Saad M; Betigeri S; Zhang M; Vetcher AA; Soldatenkov VA; Reimer DC; Pozharov VP; Minko T
    Pharm Res; 2009 Feb; 26(2):382-94. PubMed ID: 18958402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dermal/transdermal delivery of small interfering RNA and antisense oligonucleotides- advances and hurdles.
    Ita K
    Biomed Pharmacother; 2017 Mar; 87():311-320. PubMed ID: 28064104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides.
    Juliano R; Alam MR; Dixit V; Kang H
    Nucleic Acids Res; 2008 Jul; 36(12):4158-71. PubMed ID: 18558618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid conjugated oligonucleotides: a useful strategy for delivery.
    Raouane M; Desmaële D; Urbinati G; Massaad-Massade L; Couvreur P
    Bioconjug Chem; 2012 Jun; 23(6):1091-104. PubMed ID: 22372953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleic Acid Therapeutics in Huntington's Disease.
    Singh K; Roy I
    Recent Pat Biotechnol; 2019; 13(3):187-206. PubMed ID: 30747088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cationic derivatives of biocompatible hyaluronic acids for delivery of siRNA and antisense oligonucleotides.
    Han SE; Kang H; Shim GY; Kim SJ; Choi HG; Kim J; Hahn SK; Oh YK
    J Drug Target; 2009 Feb; 17(2):123-32. PubMed ID: 19012052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation of RNA interference-based drugs for pulmonary delivery: challenges and opportunities.
    Thanki K; Blum KG; Thakur A; Rose F; Foged C
    Ther Deliv; 2018 Oct; 9(10):731-749. PubMed ID: 30277138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleic Acids-based Nanotherapeutics Crossing the Blood Brain Barrier.
    Nafee N; Gouda N
    Curr Gene Ther; 2017; 17(2):154-169. PubMed ID: 28494740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
    Monine M; Norris D; Wang Y; Nestorov I
    J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angubindin-1 opens the blood-brain barrier in vivo for delivery of antisense oligonucleotide to the central nervous system.
    Zeniya S; Kuwahara H; Daizo K; Watari A; Kondoh M; Yoshida-Tanaka K; Kaburagi H; Asada K; Nagata T; Nagahama M; Yagi K; Yokota T
    J Control Release; 2018 Aug; 283():126-134. PubMed ID: 29753959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.